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SUMMARY 
Background: Mycobacterium ulcerans (MU) disease 
causes extensive destruction of tissues leaving large 
ulcers on the body. Management which consisted of 
surgical excision of the lesions is gradually being 
replaced with chemotherapy.  
Objective: To study the impact on surgery of prior 
treatment of MU disease with rifampicin and strep-
tomycin.  
Study Design: Retrospective, from September 2004 
to September 2009. 
Setting: Asunafo, Amansie West, Ahafo Ano and 
Amansie Central districts of Ghana. 
Methods: Patients who have completed 8 weeks or a 
minimum of 4 weeks treatment with rifampicin and 
streptomycin but have unhealed lesions were selected 
for surgery.  
Results: 132 patients had surgery for MU disease; 51 
at Tepa (Ahafo Ano); 36 at Agroyesum (Amansie 
West); 16 from Jacobu (Amansie Central); 29 from 
Goaso (Asunafo) districts. Their ages ranged from 4 
to 98 years, with mean age of 29.90 years, standard 
deviation of 20.74. Sites involved were: head and 
neck 1 (0.74%), upper limb 40 (29.63%), lower limb 
92 (68.15%), trunk 2 (1.48%) (N=135). The clinical 
forms were: papule 1 (0.74%), nodule 2 (1.48%), 
oedematous lesion 4 (2.96%), osteomyelitis 2 
(1.48%), ulcers 124 (91.85%), contractures 2 
(1.48%). 139 surgical procedures were performed: 
excision 25 (18.11), skin grafting 36 (26.1%), exci-
sion and skin grafting 54 (39.1%), debridem net 10 
(7.2%), sequestrectomy 2 (1.4%), regrafting 10 
(7.2%), release of contractures 2 (1.4%). 
 Conclusion: Treatment of MU disease with rifam-
picin and streptomycin improved the condition and 
minimised the extent of surgery. Combination of sur-
gery and antibiotics is necessary to prevent the de-
velopment contractures. 
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Buruli ulcer is a specific infection caused by Mycobacte-
rium ulcerans
1
 (MU) an acid fast bacillus
2
.  Analysis of 
its complete genome sequence has revealed the presence 
of a set of three large genes which produces  mycolac-
tone
3
, a toxin which has cytotoxic and immuno-
suppressive properties.
2, 4
 Infection with MU often leads 
to extensive destruction of the skin and soft tissue with 
the formation of large ulcers, usually on the legs or arms
5
 





MU disease has been classified into non-ulcerative and 
ulcerative forms.
4
 The non-ulcerative forms include the 
papule, nodule, plaque, and oedematous forms.  The ul-
cer, when fully developed, has undermined edges and is 
indurated peripherally.  The floor of the ulcer may have 
white cotton-wool-like slough
4
.  The lesion is usually 




Until the introduction of antibiotic treatment in 2004 by 
the World Health Organisation
7
 surgical treatment was 
the accepted definitive treatment.
8
 Currently it is known 
that between 30 – 50% of cases can be treated solely 
with antibiotics – namely rifampicin –streptomycin com-
bination.
3, 9
  However some cases require a combination 
of surgery and antibiotics; even in such cases it is rec-
ommended that antibiotics treatment should precede sur-




An additional classification of MU disease was intro-
duced
3,7
 with the institution of antibiotic treatment.  The 
lesions are classified into three categories according to 
size: 
Category I: a single lesion <5cm in diameter 
Category II: a single lesion between 5cm and 15cm in 
diameter 
Category III: a single lesion >15cm in diameter, multi-
ple lesions, lesions at critical sites (e.g. eye, breast, geni-
talia), and osteomyelitis. 
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Category I lesions may completely heal with antibiot-
ics treatment; some category II lesions may com-
pletely heal with antibiotics.  Category III lesions 
require both antibiotics and surgery; however multi-
ple small lesions and lesions located at critical sites 




Buruli ulcer occurs most frequently in tropical and 
subtropical areas that are marshy or near lakes or 
rivers.
2,3,10
  In Africa, Benin, Cote d’Ivoire and Ghana 
are the most endemic countries.
3.  
Cases in Ghana 
were identified in all 10 regions and in 90 (81.8%) of 





As a strategic intervention, the national Buruli ulcer 
programme organises regular community surgical 
outreach services to some endemic districts; and it 
was during such outreach programmes to Asunafo, 
Amansie-West, Ahafo-Ano and Amansie Central 
districts in Ghana, between 2005 to 2009, that this  
study  was undertaken. The objective of the study 
was to observe and document the effect of the WHO 
recommended intervention in the treatment of Buruli 
ulcer disease using antibiotics and surgery. 
 
PATIENTS AND METHODS 
A four-year retrospective study to determine the im-
pact of prior antibiotic therapy on surgery for Buruli 
Ulcer disease was undertaken within the period from 
September 2005 to September 2009.   This study was 
undertaken as part of the normal surgical outreach 
programmes of the National Buruli Ulcer Control 
Programme (NBUCP) to Goaso Government Hospi-
tal, Asunafo; St. Martin’s Catholic Hospital atAgroy-
esum, Amansie West; Tepa District Hospital, Ahafo 
Ano; St. Peter’s Hospital at Jacobu, Amansie Central. 
During this period, patients with suspected MU le-
sions were identified in the four districts by specially 
trained personnel, and referred to the district hospi-
tals where they were screened further.  A clinical 
diagnosis was made by the doctor and the patients 
were then started on rifampicin-streptomycin combi-
nation in accordance with the World Health Organi-
sation recommendations.  
 
At Tepa District Hospital confirmation of the diagno-
sis was done by a physician specialist and his team 
from Komfo Anokye Teaching Hospital, who re-
viewed the treatment and took swabs and punch bi-
opsies for polymerase chain reaction (PCR), direct 
smear examination, culture and histopathology.  At 
the other three hospitals tissue excised at surgery and 
wound swabs were sent for the above four investiga-
tions. Specimen were analysed at either Komfo Ano-
kye Teaching Hospital in Kumasi or the Kumasi Cen-
tre for Collaborative Research (KCCR) into Tropical 
Medicine.The surgical team comprised one plastic sur-
geon and one theatre nurse from Komfo Anokye Teach-
ing Hospital, in Kumasi, and was assisted by a doctor, 
anaesthetist, and theatre nurses from the district hospi-
tals.  St. Peter’s Hospital at Jacobu was not adequately 
equipped for surgery. Patients in Amansie Central Dis-
trict were operated upon at Bekwai District Hospital in 
Amansie East, about 35 km from Jacobu. In each district, 
patients with ulcers and other lesions diagnosed as MU 
disease and who had completed eight weeks, or a mini-
mum of four weeks treatment with rifampicin-
streptomycin combination, and who had residual lesions 
were selected for surgical treatment.   
 
The name, age, sex, and location of lesion were re-
corded; the patients were examined clinically as to their 
fitness for anaesthesia; the lesion was measured (widest 
diameter) and a clinical photograph taken. Surgery for 
lower limb lesions in adults was done under spinal anaes-
thesia; all other lesions were operated upon under gen-
eral anaesthesia.  Surgery involved: shaving wounds of 
excess granulation tissue and partial thickness skin graft-
ing, wound excision and immediate skin grafting, wound 
excision without grafting, wound debridement, se-
questrectomy, release of contracture and flap repair. Ex-
cised wounds which could not be grafted immediately 
were grafted after two weeks.  No wound or lesion had to 
be excised more than once.  
 
Skin grafted wounds were inspected after one week dur-
ing which time the dressing was changed.  The wound at 
the donor site was inspected after two weeks, when the 
dressing was also changed; thereafter the wounds – do-
nor and recipient sites – were dressed twice a week till 
all wounds healed.  Vaseline impregnated gauze was the 
dressing material used for both donor and recipient sites. 
Patients were included in the study if the clinical diagno-
sis of MU disease has been confirmed by any of: direct 
smear examination, culture of MU, polymerase chain 
reaction (PCR) or histopathology; have completed eight 
weeks or a minimum of four weeks of treatment with 
rifampicin-streptomycin combination; have undergone 
surgery for MU disease. 
 
RESULTS 
The study period extended from September 2005 to Sep-
tember 2009 and included 132 patients with MU disease, 
made up of 51 patients from Tepa District Hospital, 36 
from St Martin’s Hospital at Agroyesum, 16 from Bek-
wai District Hospital and 29 from Goaso Government 
Hospital. There were 67 males and 65 females; the male 
to female ratio is 1.03: 1.Their ages ranged from four 
years to 98 years with a mean age of 29.9 years, with a 
standard deviation of 20.7.   
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The highest prevalence of MU disease occurred in 
the age group 11 – 20 years; most of the  older pa-
tients, 14 (10.6%), aged 50 years and above, were 
seen at St. Martin’s Hospital at Agroyesum,  the old-
est being 98 years.  These were mostly problem cases 
referred from other endemic districts due to graft 
failure, recurrent ulcers, and contractures.  
 
Table 1 Age and Sex distribution of MU Patients in 4 
Endemic Districts 
Age Group Total (%) 
0 – 10 years 19 (14.4) 
11 – 20 years 38 (28.8) 
21 – 30 years 23 (17.4) 
31 – 40 years 16 (12.1) 
41 – 50 years 12 (9.1) 
51 – 60 years 12 (9.1) 
>61 12 (9.1) 
Total 132 (100) 
Sex   
Male  67 (50.8) 
Female 65 (49.2) 
 
A total of 135 MU lesions were found on the 132 
patients. Table 2 shows the distribution of the lesions.  
 
The clinical forms of the disease studied are shown in 
Table 3. The sizes of the MU lesions seen at the time 
of diagnosis, before the commencement of rifampicin 
and streptomycin treatment, were: category I, 10 
(7.41%); category II, 56 (41.48%); category III, 69 
(59.10%). At the time of surgery, when the patients 
had completed the rifampicin and streptomycin 
treatment, the sizes were: category I, 22 (16.30%); 








About 92% of the lesions were ulcers, most of them in 
the healing phase, after antibiotic treatment; 36 (26.0%) 
required only skin grafting; 54 (39.0%) required excision 
and immediate skin grafting.  Healing of these lesions 
occurred by the third week, except for 10 (7.2%) ulcers, 
(three from Tepa, seven from Agroyesum) where the 
grafts failed.  The wounds were debrided, and re-grafted 
after two weeks.  The wounds healed by the fourth post-
operative week.  For 25 ulcers in category I and II exci-
sion was the only procedure required; satisfactory heal-
ing occurred in four weeks. 
 
 
Figure 2 Satisfactory healing of ulcer following skin 
grafting 
 
 Table 2 Sites of Involvement of MU lesions in patients 
Studied N=135   
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After eight weeks of treatment with antibiotics 10 
ulcers, five from Tepa, three from Agroyesum, two 
from Goaso, were not healing; they were still covered 
with slough, with pale granulation tissue in the floor.  
Wound debridement was done; the wounds were 
dressed with vaseline-impregnated gauze for three 
weeks before skin grafting could be done.  Healing 
was also gradual and took about four weeks.  
 
Table 3 Clinical forms of Mycobacterium ulcerans 
Disease N=135 
LESION n % 
Papule 1 0.74% 
Nodule 2 1.48% 
Oedematous lesion 4 2.69% 
Osteomyelitis 2 1.48% 
Ulcer 124 91.85% 
Contracture 2 1.48% 
 
Bone involvement occurred in two cases in this se-
ries: one patient from Tepa who had MU infection of 
the right hand required sequestrectomy for 2 necrotic 
metacarpals; one patient from Goaso with a necrotic 
distal third of the right fibula also had sequestrec-
tomy. Both wounds healed uneventfully (Table 4).   
 
Table 4 Surgical procedures performed for MU pa-
tients N=139 
PROCEDURE TOTAL 
Excision 25 (18.0%) 
Skin grafting  36 (26.0%) 
Excision & skin 
grafting 
54 (39.0%) 
Debridement  10 (7.2%) 
Sequestrectomy  2 (1.4%) 






The management of MU disease has undergone sev-
eral changes as the pathogenesis of the disease was 
gradually elucidated. 
 
The distribution of the lesions is consistent with the 
findings of other workers
5, 6, 9
 emphasising the preva-
lence of MU lesions on the limbs, especially the 
lower limb. 
 
Initially surgical excision was the standard treatment; 
when performed at the nodular stage it was curative. 
In most endemic areas patients present late with ul-
cerated lesions; for such cases wide surgical excision 
was the treatment of choice.
2,4,11,12
  Adjunctive skin graft-




A clinical trial conducted in Ghana under the auspices of 
the World Health Organisation demonstrated that after 
daily treatment with rifampicin and streptomycin for at 
least four weeks MU could no longer be cultured from 
the lesions.
14
 The antibiotic treatment reduced the surface 
area of most lesions by more than 50%, allowing less 
extensive surgical excision.  The 6
th
 World Health Or-
ganisation Advisory Committee on MU disease recom-
mended in March 2003 the daily administration of ri-
fampicin and an aminoglycoside usually streptomycin, 
for eight weeks as the first line of treatment for all forms 




Current recommendations for treatment of MU disease 
are as follows: 
1. A combination of rifampicin and streptomy-
cin/amikacin for eight weeks as a first-line treatment 
for all forms of the active disease.  Nodules or un-
complicated cases can be treated without hospitalisa-
tion. 
2. Surgery to remove necrotic tissue, cover skin defects 
and correct deformities. 
3. Interventions to minimise or prevent disabilities. 
 
The papules and nodules were excised at St.  Martin’s 
Hospital at Agroyesum.  This hospital and its district 
being amongst the first to start active management of 
Mycobacterium ulcerans disease in Ghana have experi-
enced health workers who are able to detect the disease 
at an earlier stage.  The rarity of the earlier forms of the 
disease, and especially of the oedematous forms may be 
due to the efficacy of prior streptomycin-rifampicin 
treatment, lesions which heal with antibiotics alone are 
not seen by the surgical team; it may also be due to fail-
ure of patients to report for treatment since such lesions 
are painless and not deforming. 
 
In the present series prior antibiotic treatment did reduce 
the number of active early disease, leaving only ulcers in 
the healing phase (Figure 1). Out of a total of 132 pa-
tients only four oedematous lesions, two nodules, and 
one papule were found. The extent of surgery was also 
reduced; the main clinical form, the ulcers, required 
mostly skin grafting with very satisfactory healing 
(fig.2).  Though two cases required sequestrectomy, no 
extensive surgery such as limb amputations were re-
quired during the study period.  No ulcer needed to be 
excised more than once as in other series.
15
 In a three 
year review of management of MU disease at St Martin’s 
Hospital at Agroyesum, Asiedu and Etuaful
16  
saw a total 
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Surgery alone, without antibiotics, was the accepted 
mode of treatment: this involved 10 (9.8%) amputa-
tions, 65 (63.7%) wound excisions and skin grafting, 
25 (24.5%) wound excisions without skin grafting 
and 2 (1.9%) sequestrectomies. In the current study, 
there were no amputations; 39.0% wound excision 
and grafting; 18% wound excision and 1.4% se-
questrectomies; simple skin grafting without prior 
excision could not be done for any of the lesions 
whereas this constituted 26% in the current study. 
This limitation in the extent of surgery seen in the 
current study, compared to the former, can be attrib-
uted to prior antibiotic therapy. 
 
Healing of MU infection occurs by secondary inten-
tion after sloughing of epidermis and subcutaneous 
fat, with later re-epithelialisation.  Considerable de-
formity results from this mode of healing. On the 
extremities scarring leads to contractures, subluxation 
of joints, disuse atrophy and distal lymphoedema.
2
 
Wound excision and grafting, if performed early in 
the course of the disease, can prevent or at least 
minimise the development of contractures.  A cate-
gory three ulcer may heal by antibiotic treatment 
alone; however since healing is by secondary inten-
tion, wound contraction would be excessive, and a 
contracture may result.
17
  (Figure3) Therefore the 
suggestion by some researchers
9
 that MU disease 
could be cured with antibiotics alone should be 
viewed cautiously in terms of function of the extrem-
ity after the lesions have healed. Currently it is 
known that only early (less than six months old) and 
smaller (less than 10cm diameter) lesions can be 





Figure 3 Contracture following healing of ulcer 
 
Finally interventions to minimise or prevent disabil-
ity should not only emphasise physiotherapy; early 
medical and surgical intervention can also prevent or 
minimise the development of contractures, the main 





The introduction of antibiotic treatment for Mycobacte-
rium ulcerans disease has improved the management of 
the condition, and minimised the extent of surgery. The 
combination of antibiotic treatment and surgical inter-
vention is necessary not only to accelerate healing but 




The surgical outreach services to Asunafo, Amansie-
West, Ahafo-Ano and Amansie Central District were 
funded exclusively by the National Buruli Ulcer Control 
Programme. 
 
The surgical team is very grateful to Dr. Richard Philips 
and his medical team from Komfo Anokye Teaching 
Hospital; Dr. Akuamoah Boateng and his team from 
Tepa District Hospital; Dr. O.K. Afreh and his team from 
Goaso Government Hospital; Dr. M. Forson and his team 
from Bekwai District Hospital; and the doctors and staff 
of St. Martin’s Hospital at Agroyesum. 
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